NCT01580982Recruiting
Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung Cancer
Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung and Other Thoracic Cancers
Source: ClinicalTrials.gov · Last updated 18 Feb 2026
Brief summary (registry, in English)
The mechanisms of sensitivity and resistance to oncogene-targeted therapy can be determined from tumor tissue or tumor cell lines derived from available archival samples and/or from standard-of-care re-biopsy upon suspected tumor progression.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 17 Apr 2012
- Start date
- 23 Jan 2012
- Primary completion date
- 1 Jan 2028
- Lead sponsor
- University of Colorado, Denver
- Diseases
- Lung cancer
- NCT number
- NCT01580982
What you commit to
- Study type: Observational
- Planned participants: 500
- From 23 Jan 2012 to the primary completion date, 1 Jan 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \-
Who the study is looking for
- Patients undergoing investigation or treatment for thoracic cancers with oncogene-targeted therapies
- Aged 18 years or older
- Either a) have suspected tumor progression or other condition that dictates a standard-of-care palliative, therapeutic, or diagnostic intervention including but not limited to procedures such as bronchoscopic biopsy, computed tomography (CT) or ultra-sound (US)-guided biopsy, thoracentesis, video assisted thoracoscopic (VATS) pleurodesis, lobectomy, adrenalectomy or pleural catheter placement, providing tumor specimen appropriate molecular analysis or b) have previously had biopsy/surgical intervention with tumor tissue at University of Colorado or an outside institution available for medullar analysis.
- Patients must have the ability to understand and willingness to sign an informed consent document.
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Colorado Cancer Center Coordinator of this site? Confirm its status | Aurora | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.